Comparative Pharmacology
Head-to-head clinical analysis: COXANTO versus NAPROXEN SODIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: COXANTO versus NAPROXEN SODIUM.
COXANTO vs NAPROXEN SODIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective inhibitor of soluble epoxide hydrolase (sEH), increasing levels of epoxyeicosatrienoic acids (EETs), which have vasodilatory, anti-inflammatory, and antifibrotic effects.
Non-selective cyclooxygenase (COX-1 and COX-2) inhibitor, reducing prostaglandin synthesis.
1 g intravenous every 6 hours.
220-550 mg orally twice daily; maximum 1375 mg/day.
None Documented
None Documented
Terminal elimination half-life: 12-15 hours (prolonged to 24-30 hours in moderate-to-severe renal impairment, requiring dose adjustment)
12–17 hours (terminal); allows twice-daily dosing; prolonged in elderly and renal impairment
Renal: 70% unchanged; biliary/fecal: 20% as metabolites; 10% other
Renal: 95% (as unchanged drug, conjugated naproxen, and 6-O-desmethyl naproxen); Fecal: <5%
Category C
Category D/X
NSAID
NSAID